We may be drinking too much if the kool aid, but IMO that only addresses beliefs about short term matters, relative strength of management, perceived FDA bias and so forth.

Speaking only for myself, I came to Cytodyn after Covid erupted and it became clear to me that the pathogenicity is most, if not fully driven by immune dysfunction. The EIND successes in March, followed by Patterson’s manuscript May 5 convince me beyond a doubt that leronlimab is a real solution.

I cannot speak to what shareholders have endured in years past, but Cytodyn has availed itself of the opportunity presented by Covid and hours from success. All IMO